Imunon (NASDAQ:IMNN – Get Free Report) is expected to release its earnings data before the market opens on Thursday, February 27th. Analysts expect Imunon to post earnings of ($0.36) per share for the quarter.
Imunon Stock Down 6.2 %
Shares of Imunon stock opened at $0.86 on Tuesday. Imunon has a fifty-two week low of $0.57 and a fifty-two week high of $3.65. The firm has a market cap of $12.50 million, a PE ratio of -0.46 and a beta of 2.03. The business’s fifty day moving average is $0.90 and its two-hundred day moving average is $0.95.
Analyst Upgrades and Downgrades
A number of brokerages have weighed in on IMNN. D. Boral Capital reissued a “buy” rating and set a $29.00 price target on shares of Imunon in a research note on Wednesday, February 19th. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 target price on shares of Imunon in a research report on Thursday, December 19th.
About Imunon
Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.
Read More
- Five stocks we like better than Imunon
- Which Wall Street Analysts are the Most Accurate?
- The Behemoth BlackRock’s Next Trillion Comes From Private Assets
- How to Find Undervalued Stocks
- Rivian’s Rough Patch: Is the Dip a Doorway to Long-Term Gains?
- Growth Stocks: What They Are, What They Are Not
- Institutions Signal Opportunty to Buy High-Yield Kraft-Heinz
Receive News & Ratings for Imunon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imunon and related companies with MarketBeat.com's FREE daily email newsletter.
